Publications

  1. Taber JM, Aspinwall LG, Drummond DM, Stump TK, Kohlmann W, Champine M, Cassidy P, Leachman SA. Priority of Risk (But Not Perceived Magnitude of Risk) Predicts Improved Sun-Protection Behavior Following Genetic Counseling for Familial Melanoma. Ann Behav Med. 2020 May 16:kaaa028. doi: 10.1093/abm/kaaa028. Epub ahead of print. PMID: 32415830.
  2. Cassidy PB, Liu T, Florell SR, Honeggar M, Leachman SA, Boucher KM, Grossman D. A Phase II Randomized Placebo-Controlled Trial of Oral N-acetylcysteine for Protection of Melanocytic Nevi against UV-Induced Oxidative Stress In Vivo. Cancer Prev Res (Phila). 2017 Jan;10(1):36-44. doi: 10.1158/1940-6207.CAPR-16-0162. Epub 2016 Dec 5. PMID: 27920018; PMCID: PMC5219848.
  3. Pfeffer SR, Grossmann KF, Cassidy PB, Yang CH, Fan M, Kopelovich L, Leachman SA, Pfeffer LM. Detection of Exosomal miRNAs in the Plasma of Melanoma Patients. J Clin Med. 2015 Dec 17;4(12):2012-27. doi: 10.3390/jcm4121957. PMID: 26694476; PMCID: PMC4693157.
  4. Aspinwall LG, Taber JM, Leaf SL, Kohlmann W, Leachman SA. Genetic testing for hereditary melanoma and pancreatic cancer: a longitudinal study of psychological outcome. Psychooncology. 2013 Feb;22(2):276-89. doi: 10.1002/pon.2080. Epub 2011 Oct 7. PMID: 23382133.
  5. Hawkes JE, Cassidy PB, Manga P, Boissy RE, Goldgar D, Cannon-Albright L, Florell SR, Leachman SA. Report of a novel OCA2 gene mutation and an investigation of OCA2 variants on melanoma risk in a familial melanoma pedigree. J Dermatol Sci. 2013 Jan;69(1):30-7. doi: 10.1016/j.jdermsci.2012.09.016. Epub 2012 Oct 13. PMID: 23103111; PMCID: PMC4775076.
  6. Teerlink C, Farnham J, Allen-Brady K, Camp NJ, Thomas A, Leachman S, Cannon-Albright L. A unique genome-wide association analysis in extended Utah high-risk pedigrees identifies a novel melanoma risk variant on chromosome arm 10q. Hum Genet. 2012 Jan;131(1):77-85. doi: 10.1007/s00439-011-1048-z. Epub 2011 Jun 26. PMID: 21706340.
  7. Kadekaro AL, Leachman S, Kavanagh RJ, Swope V, Cassidy P, Supp D, Sartor M, Schwemberger S, Babcock G, Wakamatsu K, Ito S, Koshoffer A, Boissy RE, Manga P, Sturm RA, Abdel-Malek ZA. Melanocortin 1 receptor genotype: an important determinant of the damage response of melanocytes to ultraviolet radiation. FASEB J. 2010 Oct;24(10):3850-60. doi: 10.1096/fj.10-158485. Epub 2010 Jun 2. PMID: 20519635; PMCID: PMC3229421.

  1. Jeter JM, Bowles TL, Curiel-Lewandrowski C, Swetter SM, Filipp FV, Abdel-Malek ZA, Geskin LJ, Brewer JD, Arbiser JL, Gershenwald JE, Chu EY, Kirkwood JM, Box NF, Funchain P, Fisher DE, Kendra KL, Marghoob AA, Chen SC, Ming ME, Albertini MR, Vetto JT, Margolin KA, Pagoto SL, Hay JL, Grossman D, Ellis DL, Kashani-Sabet M, Mangold AR, Markovic SN, Meyskens FL Jr, Nelson KC, Powers JG, Robinson JK, Sahni D, Sekulic A, Sondak VK, Wei ML, Zager JS, Dellavalle RP, Thompson JA, Weinstock MA, Leachman SA, Cassidy PB. Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. Cancer. 2019 Jan 1;125(1):18-44. doi: 10.1002/cncr.31719. Epub 2018 Oct 3. Erratum in: Cancer. 2019 Aug 1;125(15):2706. Meyskens, Frank L, Jr [added]. PMID: 30281145; PMCID: PMC6860362.
  2. Cassidy PB, Liu T, Florell SR, Honeggar M, Leachman SA, Boucher KM, Grossman D. A Phase II Randomized Placebo-Controlled Trial of Oral N-acetylcysteine for Protection of Melanocytic Nevi against UV-Induced Oxidative Stress In Vivo. Cancer Prev Res (Phila). 2017 Jan;10(1):36-44. doi: 10.1158/1940-6207.CAPR-16-0162. Epub 2016 Dec 5. PMID: 27920018; PMCID: PMC5219848.
  3. Cassidy PB, Honeggar M, Poerschke RL, White K, Florell SR, Andtbacka RH, Tross J, Anderson M, Leachman SA, Moos PJ.The role of thioredoxin reductase 1 in melanoma metabolism and metastasis. Pigment Cell Melanoma Res. 2015 Nov;28(6):685-95. doi: 10.1111/pcmr.12398. Epub 2015 Aug 20. PMID: 26184858.
  4. Denat L, Kadekaro AL, Marrot L, Leachman SA, Abdel-Malek ZA. Melanocytes as instigators and victims of oxidative stress. J Invest Dermatol. 2014 Jun;134(6):1512-1518. doi: 10.1038/jid.2014.65. Epub 2014 Feb 27. PMID: 24573173; PMCID: PMC4418514

  1. AIM at Melanoma Foundation Opens First Melanoma Tissue Bank in the United States. Read full article.
  2. How a New Tumor Bank Is Changing Melanoma Research. Read full article.

  3. The International Melanoma Tissue Bank Consortium (video). View full video.

  1. Petrie T, Samatham R, Witkowski AM, Esteva A, Leachman SA. Melanoma Early Detection: Big Data, Bigger Picture. J Invest Dermatol. 2019 Jan;139(1):25-30. doi: 10.1016/j.jid.2018.06.187. Epub 2018 Oct 25. PMID: 30482597; PMCID: PMC6685706.
  2. Webster DE, Suver C, Doerr M, Mounts E, Domenico L, Petrie T, Leachman SA, Trister AD, Bot BM. The Mole Mapper Study, mobile phone skin imaging and melanoma risk data collected using ResearchKit. Sci Data. 2017 Feb 14;4:170005. doi: 10.1038/sdata.2017.5. PMID: 28195576; PMCID: PMC5308198.

  1. Funk T, Hansen CD, Paller A, O'Toole EA. (2020). Update on pachyonychia congenita research. Br J Dermatol. 182(3):788-789.
  2. Eliason MJ, Leachman SA, Feng BJ, Schwartz ME, Hansen CD. A review of the clinical phenotype of 254 patients with genetically confirmed pachyonychia congenita. (2012). J Am Acad Dermatol. 67(4):680-6.
  3. Hickerson RP, Leachman SA, Pho LN, Gonzalez-Gonzalez E, Smith FJ, McLean WH, Contag CH, Leake D, Milstone LM, Kaspar RL. (2011). Development of Quantitative Molecular Clinical End Points for siRNA Clinical Trials. J Invest Dermatol, 131(5), 1029-36.
  4. Hickerson RP, Flores MA, Leake D, Lara MF, Contag CH, Leachman SA, Kaspar RL. (2011). Use of Self-Delivery siRNAs to Inhibit Gene Expression in an Organotypic Pachyonychia Congenita Model. J Invest Dermatol, 131(5), 1037-44.
  5. Kaspar RL, Leachman SA, McLean WH, Schwartz ME. (2011). Toward a treatment for pachyonychia congenita: report on the 7th annual international pachyonychia congenita consortium meeting. J Invest Dermatol, 131(5), 1011-4.
  6. Leachman SA, Hickerson RP, Schwartz ME, Bullough EE, Hutcherson SL, Boucher KM, Hansen CD, Eliason MJ, Srivatsa GS, Kornbrust DJ, Smith FJ, McLean WI, Milstone LM, Kaspar RL. (2010). First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol Ther, 18(2), 442-6.).

  1. Wu YP, Boucher K, Hu N, Hay J, Kohlmann W, Aspinwall LG, Bowen DJ, Parsons BG, Nagelhout ES, Grossman D, Mooney K, Leachman SA, Tercyak KP. A pilot study of a telehealth family-focused melanoma preventive intervention for children with a family history of melanoma. Psychooncology. 2020 Jan;29(1):148-155. doi: 10.1002/pon.5232. Epub 2019 Nov 10. PMID: 31520429
  2. Wu YP, Parsons BG, Nagelhout E, Haaland B, Jensen J, Zaugg K, Caputo H, Lensink R, Harding G, Yancey J, Klein SZ, Leachman SA, Tercyak KP. A four-group experiment to improve Western high school students' sun protection behaviors. Transl Behav Med. 2019 May 16;9(3):468-479. doi: 10.1093/tbm/ibz021.

  1. Witkowski AM, Łudzik J, Arginelli F, Bassoli S, Benati E, Casari A, De
Carvalho N, De Pace B, Farnetani F, Losi A, Manfredini M, Reggiani C, Malvehy J, Pellacani G. Improving diagnostic sensitivity of combined dermoscopy and reflectance confocal microscopy imaging through double reader concordance evaluation in telemedicine settings: A retrospective study of 1000 equivocal cases. PLoS One. 2017 Nov 9;12(11):e0187748.
  2. Leachman SA, Cassidy PB, Chen SC, Curiel C, Geller A, Gareau D, Pellacani G, Grichnik JM, Malvehy J, North J, Jacques SL, Petrie T, Puig S, Swetter SM, Tofte S, Weinstock MA. Methods of Melanoma Detection. Cancer Treat Res. 2016;167:51-105. doi: 10.1007/978-3-319-22539-5_3. PMID: 26601859.
  3. Witkowski A, Łudzik J, Soyer HP. Telediagnosis with Confocal Microscopy: A Reality or a Dream?   Dermatol Clin. 2016 Oct;34(4):505-512. doi: 10.1016/j.det.2016.05.013. PMID: 27692456 Review.